The Globe and Mail: Grifols donors not informed their plasma is used for drugs sold overseas, MPs hear
Donors giving blood plasma at Grifols’ paid collection centres are not informed that some medicines made from their donations will be sold for profit overseas, according to testimony from a Canadian ...
Grifols donors not informed their plasma is used for drugs sold overseas, MPs hear
Morningstar: Grifols' Acquisition Strategy Has Raised Debt Levels, but the Narrow Moat Plasma Business Is Healthy
Market share in the global plasma-derived protein business is concentrated among a small number of global players. Grifols lifted itself to the level of competitors Takeda and CSL with the $3.7 ...
Grifols' Acquisition Strategy Has Raised Debt Levels, but the Narrow Moat Plasma Business Is Healthy
Morningstar: Grifols: Downgrading Moat and Capital Allocation Rating on Competition and Weak Balance Sheet
Grifols: Downgrading Moat and Capital Allocation Rating on Competition and Weak Balance Sheet
Spanish plasma-derived medicines company Grifols announced that it has successfully completed the refinancing of its 2027 debt maturities through a new credit agreement structured as a Term Loan B ...
Spanish plasma medicines producer Grifols is clapping back at Gotham City Research, filing a lawsuit that accuses the New York hedge fund of “knowingly making false and misleading statements” about ...
The Globe and Mail: Health Canada imposes new conditions on Grifols after deaths of two people who donated plasma
Health Canada is imposing new terms and conditions on the licences of Grifols, Canada’s only major commercial collector of blood plasma, after two people died following donations in recent months. The ...